tldrdaily.news logo
Tag

Osimertinib

All articles tagged with #osimertinib

health2 years ago

"Groundbreaking 5-Year Study Reveals Promising Results for Lung Cancer Pill"

A five-year study published in The New England Journal of Medicine has shown that the lung cancer pill, Osimertinib (Tagrisso), can reduce the risk of recurrent cancer by up to 73% and the risk of death by up to 51% in patients with Stage 1B-3A lung cancer who have a certain genetic mutation and have had surgery to remove cancerous tumors. The results have been described as "earth-shattering" by experts in the field, as the improvement in survival rates far exceeds previous expectations. The pill is part of the growing field of personalized medicine, targeting specific genetic mutations in tumors, and offers hope for lung cancer patients who were previously considered to have a fatal disease.

via New York Post |
#genetic-mutation#health#lung-cancer
health2 years ago

"Groundbreaking Study Reveals Promising Results for Lung Cancer Pill and Screening Methods"

A medication called Osimertinib, sold under the brand name Tagrisso, has shown "earth-shattering" results in a five-year study for lung cancer patients with a certain genetic mutation. The study found that Tagrisso reduced the risk of recurrent cancer by up to 73% and the risk of death by up to 51%. This targeted therapy is available to patients with Stage 1B-3A lung cancer who have had surgery to remove cancerous tumors and have the EGFR mutation. The medication aims to prevent recurrence and improve survival rates, offering hope to patients who previously faced a fatal disease.

via Fox News|
#genetic-mutation#health#lung-cancer
health2 years ago

AstraZeneca pill halves deaths from lung cancer.

AstraZeneca's drug osimertinib has been found to reduce the risk of death in some lung cancer patients by more than half, according to a three-year-long clinical trial. The drug was administered to patients with a specific gene mutation called EGFR, which accounts for about 10 to 15% of all lung cancer patients. The study showed that an estimated 88% of patients treated with the daily AstraZeneca pill were alive after years compared to 73% of the patients who received the placebo. The drug has been around for close to 10 years but has been used to treat metastatic, or stage four, lung cancer.

via KXAN.com|
#astrazeneca#clinical-trial#gene-mutation
health2 years ago

Daily pill slashes risk of lung cancer death by half.

A once-daily pill called Tagrisso, developed by AstraZeneca, has been proven to cut deaths by 51% among patients in the early stages of lung cancer who have undergone surgery, according to a multi-year international study. The drug, which is part of a class of medications called kinase inhibitors, works by blocking the signals that help cancer cells grow. The study looked at 682 patients from all over the world, with roughly half given Tagrisso once daily for three years while the other half was given a placebo. The drug has been approved for medical use in the United States and European Union for several years.

via msnNOW|
#astrazeneca#cancer-treatment#health
health2 years ago

New Lung Cancer Pill Reduces Death Risk by 50% in Clinical Trial

A global study has shown that a once-daily pill, osimertinib, reduces the risk of dying from lung cancer by over half. Taken after tumor-removal surgery, the drug was shown to lessen the risk of patient death by 51 percent worldwide. The non-placebo group observed a survival rate of 88 percent after five years, compared to the placebo group, which saw a markedly lower survival rate of 78 percent. The drug is effective for patients with a mutated EGFR gene, present in roughly a quarter of lung cancer cases worldwide.

via Futurism|
#cancer-treatment#clinical-trial#egfr-gene
health2 years ago

AstraZeneca's pill halves risk of death in lung cancer patients.

AstraZeneca's once-daily pill, Tagrisso, has been found to cut deaths in half among early-stage lung cancer patients who had undergone surgery, according to new clinical trial results. The drug, which is directed at a specific receptor that helps cancer cells grow, is already approved in more than 100 countries, including the US. The trial included people with stages 1, 2 and 3 non-small cell lung cancer, the most common type of lung cancer, and participants also had a mutation in a receptor called EGFR. The new survival data could encourage more doctors to prescribe the drug and prompt wider insurance coverage of the pill.

via NBC News|
#astrazeneca#clinical-trial#health
health2 years ago

New Lung Cancer Pill Reduces Risk of Death by Half in Patients.

AstraZeneca's lung cancer drug, osimertinib, marketed as Tagrisso, has been found to reduce the risk of death by 51% in patients whose tumours were removed surgically, according to clinical trial data presented at the American Society of Clinical Oncology meeting. The drug targets a particular type of lung cancer in patients suffering from non-small cell cancer, the most common type, and showing a particular type of mutation. The clinical trial included 680 participants at an early stage of the disease, in more than 20 countries.

via Al Jazeera English|
#astrazeneca#clinical-trial#egfr-mutation
health2 years ago

New Lung Cancer Pill Reduces Risk of Death by Half, Study Shows.

AstraZeneca's drug, osimertinib, marketed as Tagrisso, has been shown to halve the risk of death from non-small cell lung cancer in patients with a particular type of mutation. The clinical trial included 680 participants at an early stage of the disease, and the result showed that taking the tablet resulted in a 51 percent reduction in the risk of death for treated patients, compared to placebo. The drug helps prevent the cancer from spreading to other parts of the body. Osimertinib is already authorized in dozens of countries for various indications and has already been given to some 700,000 people.

via ScienceAlert|
#astrazeneca#clinical-trial#egfr-mutation
health2 years ago

Promising Cancer Treatments: Lung and Rectal Cancer Patients See Positive Results in Studies.

A daily pill called osimertinib has been found to reduce the risk of dying from lung cancer by 51%, according to a decade-long global study. The Adaura trial involved patients aged between 30 and 86 in 26 countries and looked at whether the pill could help non-small cell lung cancer patients, the most common form of the disease. Everyone in the trial had a mutation of the EGFR gene, which is found in about a quarter of global lung cancer cases, and accounts for as many as 40% of cases in Asia. The pill was proven to be “practice-changing” and should become the “standard of care” for the quarter of lung cancer patients worldwide with the EGFR mutation.

via The Guardian|
#cancertreatment#clinicaltrials#egfrmutation